Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Drug: Warfarin

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 77 results found since Jan 2013.

Significant Underuse of Warfarin in Patients with Nonvalvular Atrial Fibrillation: Results from the China National Stroke Registry
Conclusions: We found that warfarin was significantly underused in patients with known NVAF in China. Age and CHD and prestroke antiplatelet therapy were related factors.
Source: Journal of Stroke and Cerebrovascular Diseases - December 2, 2013 Category: Neurology Authors: Chunjuan Wang, Zhonghua Yang, Chunxue Wang, Yilong Wang, Xingquan Zhao, Liping Liu, David Z. Wang, Hao Li, Yongjun Wang Tags: Original Articles Source Type: research

Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non –Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke
We investigated recurrent stroke volume with nonvalvular atrial fibrillation (NVAF) patients treated with non –vitamin K antagonist oral anticoagulants (NOACs) about clinical backgrounds and number of recurrent stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - October 21, 2017 Category: Neurology Authors: Yukie Kanai, Hiroaki Oguro, Nao Tahara, Hanako Matsuda, Hiroyuki Takayoshi, Shingo Mitaki, Keiichi Onoda, Shuhei Yamaguchi Source Type: research

Outcome of Secondary Stroke Prevention in Patients Taking Non –Vitamin K Antagonist Oral Anticoagulants
In this study, to determine whether or not there is a difference in outcome in secondary stroke prevention between warfarin and NOACs, patients w ith embolic stroke with newly prescribed anticoagulants were prospectively analyzed.
Source: Journal of Stroke and Cerebrovascular Diseases - December 21, 2017 Category: Neurology Authors: Taizen Nakase, Junta Moroi, Tatsuya Ishikawa Source Type: research

Recurrent Acute Ischemic Stroke after Infective Endocarditis Caused by Streptococcus Constellatus: First Case Report and Analysis of the Case Series
Acute ischemic stroke (AIS) is highly prevalent in patients with infective endocarditis (IE) and associated with high rates of death and disability. IE presenting as an acute ischemic stroke, especially recurrent concurrence of acute anterior and posterior circulation infarct, has rarely been reported. Herein, we report a case study of a 60-year-old man with a history of aortic valve replacement and was under warfarin, presented with recurrent acute ischemic stroke which was found to have no vegetation secondary to infective endocarditis caused by Streptococcus constellatus as the embolic source.
Source: Journal of Stroke and Cerebrovascular Diseases - April 26, 2018 Category: Neurology Authors: Yumin Wang, Weili Zhao, Jun Lu, Guoli Li, Bin Peng, Hongquan Wang Tags: Case Studies Source Type: research

A Therapeutic International Normalized Ratio Results in Smaller Infarcts and Better Outcomes for Patients with Ischemic Stroke
Background: Prior studies have shown that warfarin is effective for both primary and secondary stroke prevention in individuals with atrial fibrillation. It is also known that those on warfarin with atrial fibrillation often have poorer long-term poststroke outcomes, possibly because cardioembolic strokes tend to be larger and more severe. Less is known regarding the direct effect of the international normalized ratio (INR) value at the time of stroke on severity or long-term functional status. Methods: We prospectively followed a consecutive series of 112 patients presenting to our institution with acute ischemic stroke b...
Source: Journal of Stroke and Cerebrovascular Diseases - July 16, 2019 Category: Neurology Authors: Dawn Merbach, Erin Lawrence, Dania Mallick, Elisabeth B. Marsh Source Type: research

Rivaroxaban versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation for the Secondary Prevention of Stroke: A Subgroup Analysis of J-ROCKET AF
Conclusions: The safety and efficacy profile of rivaroxaban compared with warfarin was consistent among patients in the primary prevention group and those in the secondary prevention group.
Source: Journal of Stroke and Cerebrovascular Diseases - January 24, 2013 Category: Neurology Authors: Norio Tanahashi, Masatsugu Hori, Masayasu Matsumoto, Shin-ichi Momomura, Shinichiro Uchiyama, Shinya Goto, Tohru Izumi, Yukihiro Koretsune, Mariko Kajikawa, Masaharu Kato, Hitoshi Ueda, Kazuya Iwamoto, Masahiro Tajiri, J-ROCKET AF Study Investigators Tags: Original Articles Source Type: research

Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study
In the acute phase of cardioembolic stroke in patients with nonvalvular atrial fibrillation (NVAF), the recurrence rate is high. Nonvitamin K antagonist oral anticoagulants may be appropriate for prevention of early recurrence because they have a much lower risk of hemorrhagic stroke than warfarin.
Source: Journal of Stroke and Cerebrovascular Diseases - March 14, 2016 Category: Neurology Authors: Masahiro Yasaka, Kazuo Minematsu, Kazunori Toyoda, Hiroshi Yamagami, Shinichi Yoshimura, Takehiko Nagao, Etsuro Mori, Teruyuki Hirano, Toshimitsu Hamasaki, Takenori Yamaguchi Source Type: research

Effectiveness of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin for Preventing Further Cerebral Microbleeds in Acute Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation and At Least One Microbleed: CMB-NOW Multisite Pilot Trial
Nonvitamin K antagonist oral anticoagulants (NOACs) are considered superior, or at least noninferior, to warfarin in preventing stroke or systemic embolism in patients with nonvalvular atrial fibrillation. Here, we recruited acute ischemic stroke patients with nonvalvular atrial fibrillation and at least one cerebral microbleed (CMB), and evaluated the proportion of patients who had an increased number of CMBs (%) after receiving anticoagulant therapy with NOACs or with warfarin for 12 months.
Source: Journal of Stroke and Cerebrovascular Diseases - April 17, 2019 Category: Neurology Authors: Mutsumi Yokoyama, Atsushi Mizuma, Tohru Terao, Fumiaki Tanaka, Kazutoshi Nishiyama, Yasuhiro Hasegawa, Eiichiro Nagata, Shigeru Nogawa, Hiroyuki Kobayashi, Noriharu Yanagimachi, Takashi Okazaki, Kazuo Kitagawa, Shunya Takizawa, for the CMB-NOW Study Inves Source Type: research

Multicenter prospective analysis of stroke patients taking oral anticoagulants: The PASTA registry - Study design and characteristics
The management of atrial fibrillation and deep venous thrombosis has evolved with the development of direct oral anticoagulants (DOAC), and oral anticoagulant (OAC) might influence the development or clinical course in both ischemic and hemorrhagic stroke. However, detailed data on the differences between the effects of the prior prescription of warfarin and DOAC on the clinical characteristics, neuroradiologic findings, and outcome of stroke are limited.
Source: Journal of Stroke and Cerebrovascular Diseases - October 28, 2019 Category: Neurology Authors: Satoshi Suda, Yasuyuki Iguchi, Shigeru Fujimoto, Yoshiki Yagita, Yu Kono, Masayuki Ueda, Kenichi Todo, Tomoyuki Kono, Takayuki Mizunari, Mineo Yamazaki, Takao Kanzawa, Seiji Okubo, Kimito Kondo, Nobuhito Nakajima, Takeshi Inoue, Takeshi Iwanaga, Makoto Na Source Type: research

Antithrombotic Drug Uses and Deep Intracerebral Hemorrhages in Stroke Patients With Deep Cerebral Microbleeds
Conclusions: Multivariate analysis revealed that the use of antiplatelet drugs or warfarin did not significantly influence the occurrence of deep ICH in patients with deep MBs. Antiplatelet drugs or warfarin did not significantly elevate the rate of deep ICHs in stroke patients with pre-existing deep MBs.
Source: Journal of Stroke and Cerebrovascular Diseases - September 10, 2012 Category: Neurology Authors: Toshio Imaizumi, Shigeru Inamura, Ikuhide Kohama, Kazuhisa Yoshifuji, Tatsufumi Nomura, Katsuya Komatsu Tags: Original Articles Source Type: research

Lateral Medullary Stroke in Patient with Granulomatous Polyangiitis
We report a 41-year-old man with lateral medullary infarction who developed rapidly progressive renal failure. He was diagnosed with GPA based on positive serum c-ANCA and antiproteinase 3 antibodies and demonstration of pauci-immune crescentic glomerulonephritis on kidney biopsy. He was treated with Coumadin, pulse steroids, cyclophosphamide, and plasmapheresis. He had resolution of his neurologic deficits and improvement in renal function. This case report highlights the importance to consider GPA vasculitis in the differential diagnosis of stroke in patients with development of acute kidney injury.
Source: Journal of Stroke and Cerebrovascular Diseases - October 14, 2013 Category: Neurology Authors: Olga D. Taraschenko, Colum F. Amory, Jonathan Waldman, Era K. Hanspal, Gary L. Bernardini Tags: Case Reports Source Type: research

Can Early Effective Anticoagulation Prevent New Lesions on Magnetic Resonance Imaging in Acute Cardioembolic Stroke?
Background: The timing of warfarin administration for acute ischemic stroke (AIS) patients with atrial fibrillation (Af) has not been established. We hypothesized that achieving targeted prothrombin time and international normalized ratio (PT-INR) at 2 weeks could prevent AIS patients with Af from developing a new lesion on diffusion-weighted magnetic resonance imaging (DW-MRI).Methods: Of consecutively enrolled AIS patients with Af between 2008 and 2011, we selected the patients who were given warfarin within 2 weeks of admission and had DW-MRI and blood test for PT-INR both on admission and at 2 weeks. Warfarin was st...
Source: Journal of Stroke and Cerebrovascular Diseases - August 8, 2014 Category: Neurology Authors: Eiichi Nomura, Tomohiko Ohshita, Eiji Imamura, Shinichi Wakabayashi, Hiroshi Kajikawa, Masayasu Matsumoto Tags: Original Articles Source Type: research

Protocol for Cerebral Microbleeds During the Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin Therapy in Stroke Patients With Nonvalvular Atrial Fibrillation (CMB-NOW) Study: Multisite Pilot Trial
Anticoagulants are widely used to prevent recurrence of ischemic stroke in patients with nonvalvular atrial fibrillation, but in some patients, they also cause bleeding, particularly intracranial hemorrhage. One of the independent predictors of intracerebral hemorrhage is the presence of cerebral microbleeds (CMBs); a high incidence of intracerebral hemorrhage is reported in warfarin-treated patients with multiple CMBs. Longitudinal study suggested that the presence of CMBs at baseline is a predictor of new CMBs in warfarin-treated patients.
Source: Journal of Stroke and Cerebrovascular Diseases - July 4, 2015 Category: Neurology Authors: Shunya Takizawa, Fumiaki Tanaka, Kazutoshi Nishiyama, Yasuhiro Hasegawa, Eiichiro Nagata, Atsushi Mizuma, Sachiko Yutani, Taira Nakayama, Hiroyuki Kobayashi, Noriharu Yanagimachi, Takashi Okazaki, Kazuo Kitagawa, CMB-NOW Study Investigators Source Type: research

Secondary Prevention of Stroke with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry
Prior ischemic stroke or transient ischemic attack (TIA) is a high risk for thromboembolism in patients with nonvalvular atrial fibrillation (NVAF). To clarify rates of thromboembolic and hemorrhagic events, and target intensities of warfarin for secondary prevention, a subanalysis was performed using data from the J-RHYTHM Registry.
Source: Journal of Stroke and Cerebrovascular Diseases - December 22, 2015 Category: Neurology Authors: Eitaro Kodani, Hirotsugu Atarashi, Hiroshi Inoue, Ken Okumura, Takeshi Yamashita, Hideki Origasa, J-RHYTHM Registry Investigators Source Type: research